|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Pancreatic Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Pancreatic Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Digestive System Diseases | |||||
| Digestive System Neoplasms | |||||
| Endocrine Gland Neoplasms | |||||
| Endocrine System Diseases | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Pancreatic Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| carcinoembryonic antigen peptide 1 | |||||
| hepatitis B antigen peptide | |||||
| 5 | Sponsors listed in this trial | ||||
| Duke University | |||||
| National Cancer Institute (NCI) | |||||